Ciclosporin to Protect Renal Function In Cardiac Surgery

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the potential of ciclosporin in reducing risk and degree of acute kidney injury after cardiac surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Region Skane
• Collaborator: NeuroVive Pharmaceutical AB
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Non-emergent CABG

• Written informed consent to participate

• Preoperative CyC eGFR or MDRD eGFR is 90-15.

Exclusion Criteria:

• Uncontrolled hypertension

• Hypersensitivity to ciclosporin or any of the excipients of the lipid emulsion, including egg-, soya- or peanut protein

• Pregnancy or fertile woman

• Ciclosporin treatment within 4 weeks

• Ongoing malignancy, ongoing immunosuppressive treatment, severe hepatic dysfunction, dialysis or severe infection

• Ongoing medication with dabigatran, aliskiren, bosentan, stiripentol, glibenclamid, St John's worth, or

• Off-pump surgery